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The central adenosine system and adenosine receptors play a fundamental role
in the modulation of dopaminergic neurotransmission. This is mostly achieved by
the strategic co-localization of different adenosine and dopamine receptor subtypes
in the two populations of striatal efferent neurons, striatonigral and striatopallidal,
that give rise to the direct and indirect striatal efferent pathways, respectively. With
optogenetic techniques it has been possible to dissect a differential role of the direct
and indirect pathways in mediating “Go” responses upon exposure to reward-related
stimuli and “NoGo” responses upon exposure to non-rewarded or aversive-related
stimuli, respectively, which depends on their different connecting output structures
and their differential expression of dopamine and adenosine receptor subtypes.
The striatopallidal neuron selectively expresses dopamine D2 receptors (D2R) and
adenosine A2A receptors (A2AR), and numerous experiments using multiple genetic
and pharmacological in vitro, in situ and in vivo approaches, demonstrate they can
form A2AR-D2R heteromers. It was initially assumed that different pharmacological
interactions between dopamine and adenosine receptor ligands indicated the existence
of different subpopulations of A2AR and D2R in the striatopallidal neuron. However, as
elaborated in the present essay, most evidence now indicates that all interactions can
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be explained with a predominant population of striatal A2AR-D2R heteromers forming
complexes with adenylyl cyclase subtype 5 (AC5). The A2AR-D2R heteromer has a
tetrameric structure, with two homodimers, which allows not only multiple allosteric
interactions between different orthosteric ligands, agonists, and antagonists, but also
the canonical Gs-Gi antagonistic interaction at the level of AC5. We present a model
of the function of the A2AR-D2R heterotetramer-AC5 complex, which acts as an
integrative device of adenosine and dopamine signals that determine the excitability and
gene expression of the striatopallidal neurons. The model can explain most behavioral
effects of A2AR and D2R ligands, including the psychostimulant effects of caffeine. The
model is also discussed in the context of different functional striatal compartments,
mainly the dorsal and the ventral striatum. The current accumulated knowledge
of the biochemical properties of the A2AR-D2R heterotetramer-AC5 complex offers
new therapeutic possibilities for Parkinson’s disease, schizophrenia, SUD and other
neuropsychiatric disorders with dysfunction of dorsal or ventral striatopallidal neurons.
Keywords: striatopallidal neuron, adenosine A2A receptor, dopamine D2 receptor, GPCR heteromers, adenylyl
cyclase, caffeine, akinesia, apathy
INTRODUCTION
One of the most noticeable functions of adenosine in the brain
is the ability to impose a brake on the central dopaminergic
system. This inhibitory role of adenosine is largely mediated by
the activation of one subtype of adenosine receptor, the A2A
receptor (A2AR), particularly expressed by one type of neuron
localized in the striatum, the striatopallidal neuron. The striatum
is the brain area with the highest innervation of dopamine and the
highest expression of dopamine receptors in the brain (Gerfen,
2004), and the striatopallidal neuron expresses the highest density
of A2AR and dopamine receptors of the D2 subtype (D2R)
than any other neuron in the central nervous system (Gerfen,
2004; Schiffmann et al., 2007). It is now well accepted that
adenosine controls the function of the striatopallidal neuron
through intermolecular interactions between A2AR and D2R,
with the formation of receptor heteromers.
Since its initial discovery, now more than 25 years ago
(Ferré et al., 1991b), A2AR-D2R interactions have become a
model for the study of allosteric interactions within G protein-
coupled receptor (GPCR) heteromers, with the emergence of a
new concept: allosteric interactions between orthosteric ligands
(reviewed in Ferré et al., 2014). But recent findings indicate
that the A2AR-D2R heteromer will also become a model for
receptor-receptor interactions previously thought to take place
downstream, on converging signaling molecules, which were
often labeled as “interactions at the second messenger level.”
The antagonistic canonical interaction at the level of adenylyl
cyclase (AC), between a Gs/olf-coupled receptor, such as the
A2AR, and a Gi/o-coupled receptor, such as the D2R, represents
a classical example. Thus, a recent study demonstrates that
this canonical interaction is dependent on the oligomerization
of A2AR and D2R and the AC subtype AC5 (Navarro et al.,
2018). This discovery implies that the striatal A2AR-D2R
heteromer could explain most pharmacological effects of A2AR
and D2R ligands, with implications for various neuropsychiatric
disorders.
The understanding of the role of striatal adenosine and A2AR-
D2R heteromers in striatal function and dysfunction will be here
revisited within the framework of, not only the new developments
on A2AR-D2R heteromers, but also most recent developments
on the function of different striatal compartments and striatal
dopamine, particularly on the function of the striatopallidal
neuron. First, we summarize the current knowledge of the
role of dopamine in the different striatal compartments. Next,
we analyze the role of adenosine-dopamine interactions in the
modulation of the function of the striatopallidal neuron. We then
propose a functional model for the A2AR-D2R heterotetramer-
AC5 complex in the striatopallidal neuron, a complex formed
by one A2AR homodimer coupled to a Golf protein, a D2R
homodimer coupled to a Gi protein and its signaling molecule
AC5. The model is then used to reevaluate the pharmacological
effects of adenosine receptor ligands, including caffeine. Finally,
it is proposed that A2AR-D2R heterotetramer-AC5 complexes
localized in striatopallidal neurons can be used as targets for
the treatment of neuropsychiatric symptoms, such as akinesia
and apathy. We also present new results of the effect of the
A2AR antagonist SCH 442416 in radioligand binding, locomotor
activation and optogenetic experiments in mice, which reconcile
previous studies with the same compound that were apparently
incompatible with our hypothesis of a predominant population
of striatal A2AR-D2R heteromers that modulate striatopallidal
neuronal function.
FUNCTIONAL DISTINCTION OF
STRIATAL COMPARTMENTS
The striatum is the main input structure of the basal ganglia.
Although in humans and non-human primates it has been
classically subdivided into nucleus accumbens (NAc), caudate
and putamen, it can be functionally subdivided in three different
compartments: ventral, rostral-dorsal and caudal-dorsal striata
(Figure 1A). The ventral striatum concept has expanded from
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its initial inclusion of areas innervated by the dopaminergic cells
of the ventral tegmental area (VTA), mostly the NAc with its
two compartments core and shell and the olfactory tubercle,
to the striatal areas receiving glutamatergic inputs from the
ventromedial prefrontal cortex, orbitofrontal cortex and anterior
cingulate cortex (Haber and Behrens, 2014) (Figure 1A). In
fact, the orbitofrontal cortex and the anterior cingulate cortex,
respectively, receive partial and predominant dopaminergic
innervation from the substantia nigra pars compacta (SNpc;
Haber and Behrens, 2014). Furthermore, the ventral striatum
receives afferent glutamatergic projections from the insular
cortex, amygdala and hippocampus (Haber and Behrens, 2014).
The rostral-dorsal striatum receives glutamatergic input from
frontal and parietal association areas and the caudal-dorsal
striatum from the primary motor and somatosensory cortices
(Figure 1A). Both rostral-dorsal and caudal-dorsal striata receive
their dopaminergic input from the SNpc (Haber, 2014; Haber and
Behrens, 2014).
The ventral striatum forms part of decision-making brain
circuits involved in reward valuation tasks, which determine
and store reward values (often named as “subjective values of
rewards”) and constantly choose the reward to be obtained
by a process of maximizing utilities associated with different
options, the highest benefit/cost ratio (Kable and Glimcher,
2009). ‘Delay discounting’ (DD), ‘effort discounting’ (ED), and
‘low-probability discounting’ (LPD) refer to the empirical finding
that both humans and animals value immediate, low-effort and
high probability rewards more than delayed, high-effort and
low probability rewards. A large number of behavioral and
clinical studies indicate that DD, ED, and LPD are independent
variables possibly involving corticostriatal circuits with different
ventral striatal compartments differentially connected to different
prefrontal cortical areas (Prévost et al., 2010; Stopper and
Floresco, 2011). A main role of the ventral striatum, classically
labeled as an interface between motivation and action (Mogenson
et al., 1980), can be synthesized as determining “whether
to respond” while that of the dorsal striatum is “how to
respond” to reward-associated stimuli (Ferré, 2017). All reward-
related, dopamine-dependent functions, including the facilitation
of reward-oriented behavior and learning of stimulus-reward
and reward-response associations (positive reinforcement; Wise,
2004), are simultaneously processed by the rostral-dorsal and
caudal-dorsal striata. In relation to positive reinforcement, the
rostral-dorsal striatum is predominantly involved in an initial,
more controlled (contingent on the outcome) and less permanent
learning, while the caudal-dorsal striatum is involved in a
slower, less controlled (non-contingent on the outcome) but
long-lasting learning (Kim and Hikosaka, 2015). The same
functional dichotomy, “volitional” and “automatic” learning, but
with a medial-lateral distribution, can also be demonstrated in
the rodent striatum (Voorn et al., 2004; Yin and Knowlton,
2006; Balleine and O’Doherty, 2010). However, it is becoming
increasingly evident that dopaminergic mesencephalic cells
also process aversive-related and non-rewarded stimuli and
are involved in negative reinforcement. Most dopamine cells
respond by decreasing their activity upon exposure to aversive
stimuli and to omission of expected rewards. Dopaminergic
cells, therefore, code for positive and negative reward prediction
errors, increasing their firing upon presentation of reward-
related stimuli or better than expected rewards or with the
termination of aversive-related stimuli and decreasing their firing
upon omission of reward-related stimuli or presentation of a
worse than expected reward (Steinberg et al., 2013; Chang et al.,
2016).
FIGURE 1 | Inputs and outputs of the striatum. (A) Lateral view of the striatum and amygdala (of human and non-human primates). The classical morphological
subdivision of striatal compartments in nucleus accumbens (NAc), caudate and putamen nuclei can be functionally classified according to the cortical inputs in:
ventral striatum (in green), which receives inputs from the ventromedial prefrontal cortex (vmPFC), orbitofrontal cortex (OFC), and anterior cingulate cortex (aCC);
rostral-dorsal striatum (in orange), which receives inputs from frontal and parietal association areas, such as the dorsolateral prefrontal cortex (dlPFC), premotor
cortex (PMC), and parietal cortex (PC); and caudal-rostral striatum (in purple), which receives inputs from the primary motor cortex (MC) and the somatosensory
cortex (SSC). (B) Basal ganglia circuitry. The striatonigral neuron (SN) directly connects the striatum with the output structures of the basal ganglia: the internal
segment of the globus pallidus (iGP) and the substantia nigra pars reticulata (SNpr). The striatopallidal neuron (SP) connects with the output structures by relays in
the external segment of the globus pallidus (eGP) and the subthalamic nucleus (STN); GLU, glutamate.
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THE A2AR-D2R-EXPRESSING
STRIATOPALLIDAL NEURON
In the striatum, glutamatergic and dopaminergic inputs converge
in the dendritic spines of the GABAergic medium-sized spiny
neurons, which constitute more than 95% of the striatal neuronal
population (Gerfen, 2004). There are two types of medium-
sized spiny neurons, which define the two striatal efferent
pathways that connect the striatum with the output structures
of the basal ganglia, substantia nigra pars reticulata (SNpr)
and internal segment of the globus pallidus (Figure 1B). The
striatonigral neuron constitutes the direct efferent pathway since
it connects directly with the output structures (Gerfen, 2004).
The striatopallidal neuron gives rise to the indirect efferent
pathway and connects with the pallidal complex (the external
segment of the globus pallidus and the ventral pallidum), which
connects with the output structures directly and through a relay
in the subthalamic nucleus (Gerfen, 2004) (Figure 1B). While
there are no apparent qualitative or quantitative differences
between the glutamatergic inputs impinging on the striatonigral
and striatopallidal neurons, there is a clear distinction with
the receptors that process the dopaminergic signals. Thus, the
striatonigral neuron expresses dopamine D1 receptors (D1R),
a prototypical Gs/olf-coupled stimulatory receptor (Golf in the
striatum), while the striatopallidal neuron expresses D2R, a
prototypical Gi/o-coupled inhibitory receptor (Gerfen, 2004;
Bertran-Gonzalez et al., 2008). This established scheme breaks
down in the most ventral striatal compartment, the shell of the
NAc. The most ventral striatopallidal neurons project to the
ventromedial and ventrolateral parts of the ventral pallidum,
which does not connect with the output structures or relay
in the subthalamic nucleus (Root et al., 2015). Instead, these
regions of the ventral pallidum represent output structures of the
basal ganglia themselves, since they project to the medio-dorsal
thalamus, lateral hypothalamus and lateral habenula (Root et al.,
2015). Furthermore, some ventral striatopallidal neurons also
express D1R, with some degree of co-localization but still largely
segregated from D2R (Bertran-Gonzalez et al., 2008; Frederick
et al., 2015).
A mechanism by which dopamine is directly involved with
positive and negative reinforcement is emerging from the study
of the functional role of the direct and indirect striatal efferent
pathways. Using recently developed optogenetic techniques, it
has been possible to dissect a differential role of the direct and
indirect pathways in mediating “Go” responses upon exposure
to reward-related stimuli and “NoGo” responses upon exposure
to non-rewarded or aversive-related stimuli, respectively, which
depends on their different connecting output structures and
their differential expression of dopamine receptor subtypes
(Hikida et al., 2010, 2013; Kravitz et al., 2010, 2012; Freeze
et al., 2013; Danjo et al., 2014). The differential connectivity
entails that activation of striatonigral and striatopallidal neurons
lead to qualitatively different behavioral responses, with the
most obvious being the respective facilitation and inhibition of
psychomotor activity. At this point, following Wise and Bozarth
(1987), we should make the distinction between “psychomotor”
and simply “motor” responses. Psychomotor responses, which
include forward locomotion or withdraw, have a characteristic
dependence on external stimuli; increases or decreases of
dopamine enhance or diminish the responsiveness to those
stimuli, respectively. The differential affinities of D1R and D2R
for endogenous dopamine and their respective predominant
expression in striatonigral and striatopallidal neurons provide
a fine-tuning device by which bursts and pauses of dopamine
neurons can differentially influence their activity (Roitman
et al., 2008; Bromberg-Martin et al., 2010; Macpherson et al.,
2014). Dopamine has significantly higher affinity for D2R than
for D1R. Therefore, D2R are more activated than D1R by
basal dopamine levels and are more sensitive to the effects of
dopamine pauses, while D1R are more sensitive to dopamine
bursts, to conditions of larger dopamine release. Bursts of
dopamine neurons result in large dopamine release, which
predominantly increases the activation of stimulatory D1R
and causes the direct pathway to promote high-value reward-
associated movements, whereas the lower basal dopamine
levels predominantly activate D2R, which are inhibitory and
remove activation of the indirect pathway, thus suppressing low-
value reward-associated or high-value punishment-associated
movements (Frank, 2005; Hikosaka, 2007; Dreyer et al., 2010;
Hikida et al., 2010, 2013; Kravitz et al., 2012; Danjo et al.,
2014). Nevertheless, we should not ignore the fact that D2R
are not completely occupied by endogenous dopamine and that
bursts of dopamine are also able to enhance D2R signaling,
therefore participating to the psychomotor activation guided
by the stimuli associated with the concomitant increase in
dopaminergic cell firing. However, strong dopamine receptor
activation basically promotes potentiation of corticostriatal
synapses onto the direct pathway and learning from positive
outcomes (positive reinforcement), while weak dopamine
receptor activation promotes potentiation of corticostriatal
synapses onto the indirect pathway and learning from negative
outcomes (negative reinforcement) (Frank et al., 2004; Nakamura
and Hikosaka, 2006; Shen et al., 2008; Voon et al., 2010).
Another important phenotypical difference between the
striatopallidal and striatonigral neurons is their differential
expression of adenosine receptor subtypes. The striatopallidal
neurons selectively express A2AR, in fact, the highest density
in the brain (Schiffmann et al., 2007). On the other hand,
A2AR are absent from the striatonigral neurons, which express
adenosine A1 receptors (A1R) (Ferré et al., 1997). A2AR can
then be used as a marker of the striatopallidal neuron. For
instance, to identify the function of the striatopallidal neuron,
studies using Bacterial Artificial Chromosome (BAC) transgenic
mice have targeted the regulatory elements of either the D2R
or the A2AR (Durieux et al., 2009; Valjent et al., 2009; Freeze
et al., 2013). We used BAC transgenic mouse lines that express
Cre recombinase under the control of regulatory elements of
the D2R (D2R-Cre mice) or the A2AR (A2AR-Cre mice),
allowing the selective expression of channelrhodopsin 2 (ChR2)
by striatopallidal neurons (Kravitz et al., 2010; Freeze et al.,
2013; Zwilling et al., 2014). This was achieved by bilateral
injection of an adeno-associated virus (AAV) containing a Cre-
sensitive vector with a double-floxed inverted open reading frame
encoding a fusion of ChR2 and enhanced yellow fluorescence
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protein into the dorsomedial striatum. Then, fiber-optic cannulas
implanted immediately above the injection site allowed the local
delivery of light with the concomitant selective optogenetic
activation of a large fraction of dorsal striatopallidal neurons.
Unilateral optogenetic stimulation led to significant ipsilateral
rotational behavior, while bilateral optogenetic stimulation led to
a significant decrease in locomotor activity (Kravitz et al., 2010;
Freeze et al., 2013; Zwilling et al., 2014) (Figure 2A). These results
were opposite to those obtained by the selective ablation of a
large proportion of dorsal and ventral striatopallidal neurons in
BAC transgenic A2AR-Cre mice by Cre-mediated expression of
a diphtheria toxin receptor and diphtheria toxin injection, which
led to hyperlocomotion (Durieux et al., 2009).
Altogether, these optogenetic and genetic targeting
experiments agree with the increase and decrease of “NoGo”
responses upon the respective activation or inactivation of
striatopallidal neurons. Hypo- or hyperlocomotion represents an
outcome of the respective sustained activation or deactivation of
a large number of striatopallidal neurons, which more discretely
should represent the respective facilitation and inhibition of
withdrawal behavior from low-value reward-associated or
high-value punishment-associated movements. We addressed
more directly this assumption in optogenetic experiments
with A2AR-Cre mice, by selectively inducing the expression
of ChR2 in dorsal striatopallidal neurons and by using more
discrete parameters of stimulation (Zwilling et al., 2014).
Figure 2B shows the comparison of two different parameters of
bilateral optogenetic stimulation in the dorso-medial striatum
on locomotor activity. Continuous light for 1 min induced
freezing and therefore an impairment of motor activity that
FIGURE 2 | Behavioral effects of the optogenetic stimulation of the striatopallidal neuron in mice. The adeno-associated virus (AAV) containing the Cre-sensitive
pAAV5-EF1a-DIO-hChR2(H134R)-YFP virus was bilaterally injected into the dorsal-medial striatum (1 µl at coordinates M-L ± 1.5, A-P + 0.8 and D-V –3.5, relative
to bregma) of a BAC transgenic A2AR-Cre mouse (C57BL/6 background). Fiber-optic cannulas were implanted 0.5 µm above the injection site and the virus was
allowed to incubate for 4 weeks before the start of behavioral testing. (A) At high intensity of stimulation, unilateral illumination results in rotational behavior and
bilateral illumination results in freezing. In (A) left graph, mice were unilaterally illuminated (left side) with constant light at 1 mW (measured at the fiber tip) and
anti-clockwise vs. clockwise (ipsilateral vs. contralateral) rotations were recorded for a duration of 5 min; results are expressed as mean ± SEM; Student’s paired
t-test showed significant differences in the number of rotations in the illuminated condition (light ON) compared to control (light OFF) (∗∗∗p < 0.001, n = 4). In (A) right
graph, mice were illuminated bilaterally with constant light at equal intensity (1 mW per side) and time spent immobile over a period of 1 min was determined; results
are expressed as mean ± SEM; Student’s paired t-test showed significant differences between the illuminated condition (light ON) compared to control (light OFF)
(∗∗∗p < 0.001, n = 11). (B) Comparison of different light illumination paradigms; bilateral circuit activation produced different effects on motor behavior depending on
the pattern of light stimulation; continuous light for 1 min induced freezing and motor impairment. In (B) left graph, mice were bilaterally stimulated alternating 1-min
light ON/OFF blocks, while freezing (expressed as time immobile) was scored through several cycles over 15 min (results are expressed as mean ± SEM, n = 11). In
(B) right graph, mice were pulse stimulated using a 2-s ON/8-s OFF illumination paradigm and did not exhibit ambulatory impairment; velocity of ambulation was
monitored over 3-min bins; blue and black plots represent ambulation (in mean ± SEM) of mice injected with the virus expressing ChR-YFP (n = 20) or YFP (control,
n = 10), respectively; two-way ANOVA, did not show significant differences between both groups (p > 0.05). (C) Aversive behavior driven by striatopallidal neuron
activation using stimulation parameters that did not produce motor impairment; in a real-time place-preference assay pulsed light illumination (2-s ON/8 s-OFF) was
triggered automatically upon entry into the predesignated ‘stimulation side’ of the chamber; the amount of time spent in the light-paired chamber was quantified over
20-min blocks recorded before, during and immediately after light stimulation. In (C) left graph, mice demonstrated a significant light-mediated aversion, a reduction
in the percentage of time (in mean ± SEM) spent in the stimulated side; analyzed statistically by one-way repeated measures ANOVA and Tukey post hoc test
(∗∗p < 0.01; n = 8). In (C) right panel, example tracks show robust aversion to the left stimulation chamber during the test session. (D) A2AR antagonist reduces
freezing phenotype. In (D) left graph, a 5-min pre-test injection of the A2AR antagonist SCH 442416 (3 mg/kg, i.p.) significantly reduced the percent time freezing
(in mean ± SEM) at light power levels of 0.075 mW; Student’s paired t-test showed significant difference between the groups treated with and without SCH 442416
(∗∗∗p < 0.001; n = 11). In (D) right panel, example tracks showing SCH-mediated counteraction of optogenetically induced freezing. All behaviors were performed
in custom-built arenas and activity monitored and automatically scored using a Noldus Ethovision video tracking system.
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would interfere with the analysis of behavior in a real-time
place-preference study. On the other hand, mice that were
pulse-stimulated using a 2-s ON/8-s OFF illumination paradigm
did not demonstrate ambulatory impairment (Figure 2B).
When this pulse-stimulation was triggered when the mouse
entered one of the chambers of a place-preference box, the
animal showed a very significant aversion-like behavior to
that side (Figure 2C) (Zwilling et al., 2014). These results also
complement those obtained by Hikida et al. (2010, 2013) in
experiments with selective bilateral inactivation of the dorsal
or ventral striatopallidal neuron by means of doxycycline-
dependent, pathway-specific expression of tetanus toxin (driven
by the promoter of the gene coding the neuropeptide enkephalin,
selectively expressed by striatopallidal neurons). A counteraction
of the expression in addition to the acquisition of aversion-like
behavior was also demonstrated by using an asymmetric design,
with targeted unilateral inactivation of the ventral striatopallidal
neurons with tetanus toxin and the contralateral infusion of
a D2R agonist (but not a D2R antagonist or D1R agonists
or antagonists) or an A2AR antagonist (Hikida et al., 2013).
Similarly, we could demonstrate that the systemic administration
of the A2AR antagonist SCH 442416 (3 mg/kg i.p.) significantly
decreases the locomotor depression induced by low-intensity
optogenetic stimulation of the dorsal-medial striatopallidal
neurons (Figure 2D). These results would imply a significant
role of an endogenous adenosinergic tone in the facilitation of
the striatopallidal neuronal function mediated by A2AR. In fact,
numerous neurochemical studies imply that A2AR signaling is
especially involved in driving the activation of the striatopallidal
neuron upon D2R disinhibition (see below), therefore in driving
the suppression of the behavior associated with non-rewarded
and punishment-associated stimuli.
THE A2AR-D2R RECEPTOR
HETEROTETRAMER-AC5 COMPLEX
There is a large amount of experimental evidence indicating
the existence of a predominant striatal population of A2AR and
D2R that control striatopallidal neuronal function (Ferré et al.,
1993, 2016; Azdad et al., 2009; Bonaventura et al., 2015). Recent
studies suggested that A2AR-D2R heteromers assemble into a
heterotetrameric structure, with A2AR and D2R homodimers
coupled to their respective cognate Gs (more precisely the
Golf isoform) and Gi proteins (Bonaventura et al., 2015). The
heterotetrameric structure would provide the frame for multiple
adenosine-dopamine interactions and for interactions between
exogenous A2AR and D2R ligands (Navarro et al., 2014; Ferré
et al., 2016). One of the most prominent interactions is the
allosteric negative effect of A2AR ligands on the affinity and
efficacy of D2R ligands (allosteric interaction) (Ferré et al.,
1991b; Azdad et al., 2009; Bonaventura et al., 2015), which has
been demonstrated to depend on A2AR-D2R heteromerization
by the use of synthetic peptides that selectively interfere with
the heteromeric interface, both in mammalian transfected cells
and in striatal tissue (Azdad et al., 2009; Bonaventura et al.,
2015).
In addition to the allosteric interaction, a strong reciprocal
antagonistic interaction, with the ability of D2R agonists to
inhibit A2AR agonist-mediated activation of AC, was first
identified in mammalian transfected cells (Kull et al., 1999;
Hillion et al., 2002) and more recently characterized in
striatal cells in culture (Navarro et al., 2014). This represents
an antagonistic Gs-Gi canonical interaction, the ability of
an activated Gi-coupled receptor to inhibit a Gs-coupled
receptor-mediated activation of AC. The A2AR-D2R canonical
interaction was first observed in situ, in the striatum. The
evidence came initially from experiments that demonstrated
that the increase in the expression of the immediate-early gene
c-fos in the striatopallidal neurons upon treatment with D2R
antagonists or acute dopamine depletion could be counteracted
by blocking A2AR signaling (Boegman and Vincent, 1996;
Svenningsson et al., 1999). This A2AR signaling is initiated
by the second messenger cyclic-AMP (cAMP), the product of
AC activation. The cascade includes protein kinase A (PKA)
activation, with phosphorylation of the cAMP-response element
binding protein (CREB), a mechanism which is amplified
by the PKA-dependent phosphorylation of ‘dopamine- and
cAMP-regulated phosphoprotein of molecular weight 32,000’
(DARPP-32) (Svenningsson et al., 1998; Kull et al., 1999)
(Figure 3A). A2AR-mediated activation of PKA also promotes
phosphorylation of voltage dependent Ca2+ channels (VDCC),
NMDA, and AMPA receptors (Håkansson et al., 2006; Azdad
et al., 2009; Higley and Sabatini, 2010), which determines their
degree of activation and, therefore, the degree of excitability
of the striatopallidal neurons, which determines the degree of
psychomotor depression (Figure 3A).
Activation of the D2R, when uninterrupted by co-activation
of the A2AR (allosteric interaction), can also signal through
phospholipase C (PLC) by a Gßγ subunit-dependent mechanism,
which induces the release of inositol (1,4,5)-triphosphate (IP3),
a second messenger that causes the release of intracellular
Ca2+. This, in turn results in the subsequent activation of the
Ca2+/calmodulin-dependent protein phosphatase calcineurin
(also called protein phosphatase 2B or PP2B) (Hernandez-Lopez
et al., 2000; Azdad et al., 2009) (Figure 3A). Phosphorylated
forms of VDCC, NMDA, and AMPA receptors and DARPP-32
are main targets of PP2B. Therefore, activation of PP2B leads to
a decreased neuronal excitability and represents a downstream
additional mechanism of D2R-mediated inhibition of A2AR
signaling (Lindskog et al., 1999) (Figure 3A). In addition,
A2AR and D2R activation can modify gene expression through
respective G protein-dependent and independent mechanisms
of MAPK activation, which plays a predominant role in the
mailing of signals from the synapse to the nucleus by directly
activating the constitutive transcription factor Elk-1 (Besnard
et al., 2011) (Figure 3A). Our previous work indicates that
the outcome of co-activation of striatal A2AR and D2R on
MAPK activation depends on the intracellular levels of Ca2+,
which determines the binding of two different neuronal Ca2+-
binding proteins, NCS-1 and calneuron-1 (Navarro et al., 2014).
NCS-1 and calneuron bind to the A2AR-D2R heteromer upon
low and high concentrations of Ca2+, respectively. Binding
of calneuron specifically alters the ability of A2AR ligands
Frontiers in Pharmacology | www.frontiersin.org 6 April 2018 | Volume 9 | Article 243
fphar-09-00243 April 6, 2018 Time: 17:35 # 7
Ferré et al. A2AR-D2R-AC5 Complexes Control Striatopallidal Neurons
FIGURE 3 | The A2AR-D2R heterotetramer. (A) Model representing the striatal A2AR-D2R heteromer-dependent mechanisms that modulate different biochemical
and behavioral outputs. The heterotetrameric structure of the A2AR-D2R heteromer allows multiple simultaneous and reciprocal interactions between adenosine and
dopamine and exogenous A2AR and D2R ligands. Mainly, the ability of adenosine or exogenous A2AR ligands to decrease G protein-dependent (1) or G
protein-independent (2) signaling by dopamine or exogenous D2R ligands (allosteric interactions) and a reciprocal antagonistic interaction, the ability of D2R agonists
to inhibit the A2AR agonist-mediated activation of AC5, by means of the antagonistic Gs-Gi canonical interaction at the AC5 level (3). When uninterrupted by the
canonical interaction, A2AR signals through activation of AC5 and protein kinase A (PKA) with phosphorylation of ‘dopamine- and cAMP-regulated phosphoprotein
of molecular weight 32,000’ (DARPP-32), which facilitates PPI and catalepsy, and voltage-dependent Ca2+ channels (VDCC), NMDA and AMPA receptors, resulting
in an increase in the excitability of the striatopallidal neuron. When uninterrupted by the allosteric interaction, D2R signals through PLC, which leads to activation of
calcineurin (PP2B). PP2B dephosphorylates PKA substrates, DARPP-32, VDCC, NMDA and AMPA receptors, providing a downstream additional mechanism of
D2R-mediated inhibition of A2AR signaling (4) and leading to a decrease in the excitability of the striatopallidal neuron, which facilitates psychomotor activation.
A2AR and D2R activation can also modify gene expression through different mechanisms, including G protein-dependent and independent MAPK activation and
activation of the transcription factor Elk-1 (see text). In (B,C), schematic slice-representation viewed from the extracellular side of the minimal functional unit of the
A2AR-D2R heterotetramer in complex with AC5 (see text), in the absence (B) and presence (C) of agonists, which induce a rearrangement of the
heterotetramer-AC5 interfaces (modified from Navarro et al., 2018).
to allosterically modulate the GTP-independent D2R ligand-
mediated MAPK activation, while binding of NCS-1 also
counteracts the A2AR-mediated allosteric modulation of D2R-
ligand-mediated G protein signaling (and therefore the canonical
interaction). This provides a mechanism by which co-activation
of A2AR and D2R in the heteromer promotes and counteracts
MAPK activation upon low and high concentrations of Ca2+,
respectively (Navarro et al., 2014).
The question is how two apparently simultaneous reciprocal
interactions between A2AR- and D2R signaling (allosteric and
canonical interactions) can take place in the same cell. Based
on some studies obtained with the A2AR antagonist SCH
442416, we initially hypothesized the existence of two populations
of A2AR in striatopallidal neurons (Orrú et al., 2011b). One
population would be forming heteromers with D2R and would
mediate the allosteric interaction, while another population
would not be forming heteromers with D2R and would allow
the antagonistic interaction at the second messenger level, cAMP
(Ferré et al., 2011; Orrú et al., 2011b). However, we recently
hypothesized that the putative heterotetrameric structure of the
A2AR-D2R heteromer could sustain both the allosteric and the
canonical interactions (Navarro et al., 2014). In addition, based
on the emergent view that considers GPCR homodimers as
main functional units (Ferré et al., 2014), we postulated that
heteromers are constituted by different interacting homodimers
(Ferré et al., 2014; Ferré, 2015). This could be of special functional
importance with heteromers formed by one homodimer coupled
to a Gs/olf protein and another different homodimer coupled
to a Gi/o protein. Our hypothesis was that such a GPCR
heterotetramer would be part of a pre-coupled macromolecular
complex that also includes AC5, the predominant AC subtype
in the striatum (Lee et al., 2002), a necessary frame for the
canonical antagonistic interaction at the AC level (Ferré, 2015).
In fact, in mammalian transfected cells, using synthetic peptides
with amino acid sequences of all transmembrane domains (TM)
of A2AR and D2R and the putative TMs of AC5, we recently
provided clear evidence for the existence of functional pre-
coupled complexes of A2AR and D2R homodimers, their cognate
Golf and Gi proteins and AC5 (Navarro et al., 2018). We
first identified a symmetrical TM 6 interface for the A2AR
and D2R homodimers and a symmetrical TM 4/TM 5 A2AR-
D2R heteromeric interface. Computational analysis provided
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one minimal solution, a linear arrangement with two internal
interacting A2AR and D2R protomers and two external non-
interacting A2AR and D2R protomers which interact with the
α-subunits of the corresponding Golf and Gi proteins (Figure 3).
Second, we found asymmetrical interfaces formed by TMs of
the receptors and putative TMs of AC5 which rearrange upon
agonist exposure. Computational analysis indicated the existence
of a minimal functional complex formed by two A2AR-D2R
heterotetramers and two AC5 molecules (Figures 3B,C). In
fact, this quaternary structure suggests the possible formation of
zig-zagged arranged high-order oligomeric structures, a higher-
order linear arrangement of GPCR heteromers and effectors
(Navarro et al., 2018). Finally, we could demonstrate that this
macromolecular complex provides the sufficient but necessary
condition for the canonical Gs-Gi interactions at the AC level
(Navarro et al., 2018). The most demonstrative experiment was
that destabilization of the quaternary structure of the A2AR-
D2R heterotetramer, with interfering synthetic peptides with
the amino acid sequence of the TMs involved in heteromeric
interface, blocked the ability of a D2R agonist to counteract AC5
activation by an A2AR agonist in striatal neurons in culture
(Navarro et al., 2018).
The A2AR-D2R heterotetramer therefore acts as an integrative
molecular device, which allows reciprocal antagonistic
interactions between adenosine and dopamine to facilitate
a switch in the activation-inhibition of the striatopallidal neuron:
A preferential A2AR vs. D2R activation leads to an increase in
neuronal activity determined by the A2AR-mediated activation
of the AC5/PKA pathway, which is potentiated by the allosteric
counteraction of D2R signaling (“1” and “2” in Figure 3A);
a preferential D2R vs. A2AR activation leads to a decrease in
neuronal activity by activation of the PLC/PP2B pathway and
switching off the A2A-mediated activation of AC5 through the
canonical interaction (“3” in Figure 3A), which we have shown
depends on the integrity of the A2AR-D2R heterotetramer-AC5
complex (Azdad et al., 2009; Higley and Sabatini, 2010; Navarro
et al., 2014, 2018; Bonaventura et al., 2015; Ferré, 2016; Ferré
et al., 2016).
The heterotetrameric structure of the A2AR-D2R heteromer
provides the framework for allosteric mechanisms of A2AR
ligands that could explain recent experimental findings
apparently incompatible with classical pharmacology, such as
the agonist-like behavior of A2AR antagonists, which includes
caffeine, a non-selective adenosine receptor antagonist. The
initial unexpected finding came from a human PET study. In
this study, the acute administration of caffeine produced an
increase in the binding of [11C]raclopride, a D2R antagonist, in
the putamen and ventral striatum (Volkow et al., 2015). As a
significant additional finding, the caffeine-dependent increase
in D2R antagonist binding in the ventral striatum correlated
with an increase in alertness (Volkow et al., 2015). Considering
that previous studies demonstrated antagonistic allosteric
interactions between A2AR and D2R agonists, caffeine should
have induced the opposite effect, a decrease in [11C]raclopride
binding, due to an increase in the affinity of endogenous
dopamine. We therefore studied the possibility of a direct
allosteric modulation of caffeine on D2R agonist binding. Both
the A2AR agonist CGS 21680 and caffeine significantly decreased
the binding of the D2R agonist [3H]quinpirole in membrane
preparations from sheep striatum and mammalian cells
transfected with A2AR and D2R. We could also demonstrate
that both agonist-agonist and antagonist-agonist allosteric
modulations were dependent on heteromerization, since they
were not observed when transfecting a mutated A2AR with
impaired ability to heteromerize with D2R (Bonaventura et al.,
2015). Therefore, we initially assumed that the caffeine-induced
increase in [11C]raclopride binding demonstrated in PET
experiments could be explained by a caffeine-induced decrease in
the affinity of endogenous dopamine. However, the observation
that both A2AR agonists and A2AR antagonists can produce
the same allosteric interaction in the A2AR-D2R heteromer, a
reduction in the affinity of agonists for the D2R, contradicts
the hypothesis of a key role of allosteric interactions within the
A2AR-D2R heteromer as a main mechanism involved in the
opposite behavioral effects of A2AR agonists and antagonists
(Ferré, 2008, 2016). Nevertheless, a biphasic effect was observed
when analyzing the effect of increasing concentrations of caffeine
or the selective A2AR antagonists SCH 58261 and KW 6002 on
the ability of a single concentration of CGS 21680 to decrease
[3H]quinpirole binding. Low concentrations of caffeine and
the A2AR antagonists significantly counteracted the effect
of CGS 21680, while high concentrations further decreased
[3H]quinpirole binding (Bonaventura et al., 2015). Therefore, the
results implied that orthosteric A2AR agonists and antagonists
produce the same allosteric modulation of D2R agonist binding
within the A2AR-D2R heteromer when applied individually, but,
when co-applied, they cancel out each other’s effect. This could be
explained by the existence of two A2AR protomers in the A2AR-
D2R heteromer and allosteric interactions between orthosteric
agonists and antagonists, by which simultaneous occupation of
the A2AR homodimer by an agonist and an antagonist would
“freeze” the ability of either ligand to allosterically modulate
D2R agonist binding. The existence of allosteric interactions
between orthosteric A2AR agonists and antagonists could be
confirmed through binding kinetics experiments with the A2AR
antagonist [3H]ZM 241385. Thus, when analyzing the effect of
CGS 21680, caffeine and SCH 58261, only CGS 21680 modified
the dissociation rate of [3H]ZM 241385 (Bonaventura et al.,
2015). Considering that CGS 21680 and [3H]ZM 241385 bind to
the same orthosteric site (Lebon et al., 2011), the effect of CGS
21680 could be explained by co-occupation of both ligands of the
two orthosteric sites in an A2AR homodimer.
The same allosteric effects on D2R agonist binding
demonstrated by A2AR agonists and antagonists were also
shown in functional experiments. By measuring ERK1/2
phosphorylation in transfected cells, we could demonstrate that
CGS 21680 counteracts quinpirole-induced MAPK activation,
that this effect of CGS 21680 can be counteracted by low
concentrations of caffeine or the A2AR antagonist SCH 58261
and that high concentration of the antagonists induce the
opposite effect (Bonaventura et al., 2015). We should therefore
expect that in the experimental animal A2AR antagonists
behave as A2AR agonists under specific conditions. In fact, in
patch-clamp experiments, we could demonstrate that the A2AR
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antagonist SCH 58261 counteracts the D2R antagonist-like
properties of CGS 21680, but it reproduces the effect of the
A2AR agonist when administered alone (Bonaventura et al.,
2015). These results challenge the traditional view of competitive
antagonism as the mechanism of the psychostimulant effects
of caffeine (and selective A2AR antagonists). According to our
model, the psychostimulant effect of caffeine can be explained by
the counteraction of the allosteric interaction by co-occupation of
the A2AR homodimer with caffeine and endogenous adenosine
in the A2AR-D2R heterotetramer.
However, these allosteric interactions between A2AR agonists
and antagonists and D2R agonists do not yet explain the
increase in striatal [11C]raclopride binding in human PET
experiments induced by caffeine. Again, counteraction by caffeine
of the inhibitory effect of endogenous adenosine on the
binding of endogenous dopamine should lead to a decrease of
[11C]raclopride binding. It was then demonstrated that CGS
21680 and caffeine also inhibit the binding of [3H]raclopride
binding in membrane preparations from striatum or transfected
cells (Bonaventura et al., 2015). That these results imply allosteric
interactions within the A2AR-D2R heteromer was demonstrated
by their disappearance upon transfection of a mutated A2AR
with impaired ability to heteromerize with D2R and by using
a synthetic peptide that disrupts A2AR-D2R heteromerization
(Bonaventura et al., 2015). Therefore, within the A2AR-D2R
heteromer, any orthosteric A2AR ligand, agonist or antagonist,
exerts a negative allosteric modulation on the affinity of any
orthosteric D2R ligand, agonist or antagonist. Finally, the same
as with [3H]quinpirole binding, we could also demonstrate a
biphasic effect of caffeine on CGS 21680-mediated decrease
of [3H]raclopride binding (Bonaventura et al., 2015). These
results would at last provide a plausible mechanism for the
effect of caffeine on [11C]raclopride binding in humans, by its
ability to antagonize the effect of endogenous adenosine on
the binding of the exogenous D2R antagonist. An alternative
explanation could still be that caffeine blocks an adenosine-
mediated internalization of A2AR-D2R heteromers (Hillion
et al., 2002; Huang et al., 2013), thus leading to higher D2R
availability along with higher [11C]raclopride binding. The
positive association between caffeine-induced increases in D2R
availability and caffeine-induced increases in alertness (Volkow
et al., 2015) would support this interpretation, since increased
D2R signaling contributes to alertness (Isaac and Berridge, 2003).
Irrespective of the mechanism involved, the effect of caffeine
on [11C]raclopride binding in human PET experiments implies
its dependence on the A2AR-D2R heteromer and, therefore,
that a significant proportion of striatal [11C]raclopride binding
visualized with PET labels A2AR-D2R heteromers. Furthermore,
these results call for the need to control caffeine intake when
evaluating the effect of D2R ligands in humans, not only when
using them as probes for imaging studies, but also when using
them as therapeutic agents in neuropsychiatric disorders.
Very different qualitative differences between several A2AR
antagonists emerged when evaluating their potencies and
efficacies on different in vitro and in vivo techniques. Particularly
significant was the demonstration of different binding properties
of the A2AR antagonist SCH 442416 depending on the presence
and absence of D2R, when forming or not forming heteromers
with D2R (Orrú et al., 2011a). In cells expressing A2AR and D2R,
competitive-inhibition curves of the A2AR antagonist [3H]ZM
241388 binding vs. increasing concentrations of SCH 442416
were clearly biphasic. On the other hand, in cells expressing only
A2AR, or A1R and A2AR, the curves were monophasic. When
analyzing the radioligand binding experiments with the two-state
dimer model (Casadó et al., 2007; Ferré et al., 2014), the data
indicated a negative cooperativity of SCH 442416 binding to
the A2AR (Orrú et al., 2011b; Ferré et al., 2014), an additional
demonstration of A2AR homomerization. This, in fact, was the
first indication that the A2AR-D2R comprises at least two A2AR
protomers, in agreement with a tetrameric structure of the A2AR-
D2R heteromer. We have now been able to reproduce these
findings in striatal tissue, comparing the results of competitive-
inhibition experiments of [3H]ZM 241388 binding vs. increasing
concentrations of SCH 442416 in striatal membrane preparations
of wild-type (WT) and striatal D2R knockout mice with a
CRE-mediated deletion of D2R expression in A2AR-expressing
neurons. The same as with mammalian transfected cells, the
curves were biphasic or monophasic in the presence or absence of
the D2R, respectively (Figure 4). The demonstration of the same
binding properties of SCH 442416 in striatal tissue than in A2AR-
D2R transfected cells implies that the A2AR-D2R heterotetramer
represents the predominant population of A2AR and D2R in
the striatum. Nevertheless, as mentioned below, striatal A2AR
are also localized presynaptically, in glutamatergic terminals,
where most probably do not form heteromers with D2R. These
receptors, although playing a significant role in the modulation
of striatal glutamate release, represent a very small fraction of the
total of striatal A2AR, as compared to the postsynaptic A2AR.
REVISITING THE BEHAVIORAL EFFECTS
OF ADENOSINE RECEPTOR LIGANDS IN
THE FRAME OF ONE MAIN POPULATION
OF STRIATAL A2AR AND D2R FORMING
HETEROMERS
Considering that increases or decreases in the activity of
the GABAergic striatopallidal neuron lead to the respective
opposite effect on psychomotor activity and using a model
that considers the A2AR-D2R heteromer as a key modulator
of striatopallidal neuronal function, we could recently explain
most psychomotor effects of caffeine (Ferré, 2016). This
included the enigmatic caffeine-induced rotational behavior in
rats with unilateral striatal dopamine denervation (Fuxe and
Ungerstedt, 1974; Herrera-Marschitz et al., 1988; Casas et al.,
1989; Garrett and Holtzman, 1995) and the ability of caffeine
to significantly counteract the adipsic-aphagic syndrome in
rodents with 6-hydroxy-dopamine-induced or genetic-induced
dopamine deficiency (Casas et al., 2000; Kim and Palmiter, 2003,
2008). According to the model, under resting conditions there
is a tonic activation of A2AR and D2R by the endogenous
neurotransmitters which results in a predominant A2AR vs. D2R
signaling and a predominant allosteric interaction (Figure 5A),
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FIGURE 4 | Specific A2AR-D2R heteromer-dependent properties of SCH
442416 in mouse striatum. Transgenic conditional knockout striatopallidal
neuron-Drd2-KO mice were generated by crossing mice expressing Cre
driven by regulatory elements of the A2AR gene (Adora2a)
[B6.FVB(Cg)-Tg(Adora2a-Cre)KG139Gsat/Mmucd; GENSAT; 036158-UCD]
with mice carrying conditional D2R gene (Drd2) null alleles
B6.129S4(FVB)-Drd2tm1.1Mrub/J,JAX020631 (Bello et al., 2017). Membrane
preparations from the striatum of striatopallidal-Drd2-KO (red) and their CRE
negative littermates (WT, black) were incubated with [3H]ZM 241385 (2 nM)
and increasing concentrations of SCH 442416 as described elsewhere
(Bonaventura et al., 2015). Data points were fit to the two-state dimer
receptor model (Casadó et al., 2007; Ferré et al., 2014), showing a biphasic
curve due to negative cooperativity of SCH 442416 in WT mice (DCB = –1.8),
but a monophasic curve in the conditional D2R null mice, thus reproducing
the same behavior of SCH 442416 previously demonstrated in mammalian
cells co-expressing A2AR and D2R and only A2AR, respectively (Orrú et al.,
2011a).
which results in low psychomotor activity. Reward-related
stimuli and, particularly a “better than expected” rewarding
stimulus (positive reward prediction error), leads to striatal
dopamine release with a predominant D2R vs. A2AR signaling,
potentiated by the canonical interaction (Figure 5B), leading to
psychomotor activation. Aversive-related stimuli or a “worse than
expected” rewarding stimuli (negative reward prediction error)
leads to inhibition of dopamine release, to the weakest D2R and
strongest A2AR signaling, which is potentiated by the canonical
interaction (Figure 5C), leading to psychomotor arrest.
A pathogenic hallmark of akinesia in Parkinson’s disease is a
pronounced hyperactivity of the striatopallidal neuron associated
with the dopamine deficiency and pronounced decrease in the
tonic D2R signaling. The discoveries on A2AR localization and
function in striatopallidal neurons gave the rational for the
recently implemented A2AR antagonists in this disease (Müller
and Ferré, 2007; Morelli et al., 2009; Armentero et al., 2011).
It was initially suggested that the value of A2AR antagonists as
antiparkinsonian agents would depend mostly on the allosteric
interaction, on the ability of A2AR antagonists to potentiate D2R
signaling by concomitant administration of L-dopa or a selective
D2R agonist (Ferré et al., 1991b, 1992). This was followed by
behavioral studies with genetic inactivation of A2AR and D2R,
which stressed the value of the canonical interaction, which
was assumed to be independent of intermolecular interactions
between A2AR and D2R (Chen et al., 2001). As mentioned above,
the existence of the two apparently incompatible simultaneous
allosteric and canonical interactions led to the hypothesis of
the existence of two populations of A2AR in the striatopallidal
neuron, one population forming heteromers with D2R and
sustaining the allosteric interaction and another population not
forming heteromers with D2R and sustaining the canonical
interaction (Ferré et al., 2011; Orrú et al., 2011b). The unique
pharmacological properties of SCH 442416, with its specific
reduced affinity for the A2AR-D2R heteromer, due to negative
cooperativity, were then exploited to attempt a pharmacological
dissection of the two populations of postsynaptic A2AR. In fact,
we previously used this strategy to dissect postsynaptic from
presynaptic A2AR, which forms heteromers with A1R in the
striatal glutamatergic terminals, where they play an important
role in the modulation of glutamate release (Ciruela et al.,
2006; Quiroz et al., 2009). A correlation had been shown with
the higher potency of SCH 442416 to block presynaptic A1R-
A2AR heteromers vs. postsynaptic A2AR-D2R heteromers and
its higher potency to inhibit corticostriatal glutamate release
than to produce locomotor activation (Orrú et al., 2011a). The
preferential presynaptic profile of SCH 442416 was confirmed
by other studies including other research groups (Hobson et al.,
2013; O’Neill et al., 2014) and was suggested to provide a
therapeutic approach for conditions with increased corticostriatal
transmission, such as cannabinoid use disorder (Justinová et al.,
2014). An apparently stronger potency of SCH 442416 to
counteract locomotor depression induced by the D2R antagonist
raclopride, as compared to that produced by the A2AR agonist
CGS 2160, was then interpreted as the ability of SCH 442416 to
also dissect the two putative postsynaptic populations of A2AR.
The more sensitive population to SCH 442416 would be A2AR
that do not form heteromers with D2R and that would sustain the
canonical interaction (Orrú et al., 2011b). However, as mentioned
before, we now know that the canonical interaction requires
receptor heteromerization (Navarro et al., 2018). Therefore, we
recently performed new studies on the behavioral effects of
SCH 442416 upon genetic blockade of A2AR or D2R and upon
administration of the A2AR agonist CGS 21680 and the D2R
antagonist haloperidol, to reevaluate if they could all be explained
within the framework of a predominant population of striatal
postsynaptic A2AR-D2R heteromers (Taura et al., 2017).
To control strain-dependent behavioral differences and
differences in drug responses, using CRISPR-Cas9 technology,
we generated a D2R deficient mouse with the same genetic
background as the CD-1 A2AR−/− mouse (Ledent et al., 1997).
CD-1 D2R−/− mice showed a significant but relatively small
reduction in spontaneous locomotor activity (Taura et al., 2017),
as previously reported in D2R−/− C57BL/6 mice (Baik et al.,
1995). This is in contrast with the pronounced akinesia and
catalepsy that characterize pharmacological D2R blockade (Ferré
et al., 1990; Kanda et al., 1994; Shiozaki et al., 1999). Therefore,
genetic D2R blockade is associated with neuroadaptations that
counteract the loss of a D2R-mediated tonic stimulatory effect
of endogenous dopamine on psychomotor activity. Indeed, a
recent study in inducible D2R knockout adult mice that obviated
developmental compensations reported that the loss of D2R was
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FIGURE 5 | Model of the striatal A2AR-D2R receptor heteromer as a main
modulator of the excitability of the striatopallidal neuron. The relative thickness
(and close number) of the red and green input arrows represents the degree
of activation of the A2AR and the D2R that depends on the concentration of
the corresponding neurotransmitter or exogenous ligands. The thickness (and
close number) of the red and green output arrows represents the intensity of
A2AR and D2R signaling, respectively, which depends on the input signal for
each receptor and on the predominance of either the antagonistic or the
canonical interaction (represented by horizontal arrows with a minus enclosed
sign). Predominant psychomotor activation or depression will result when
subtraction of the A2AR signaling from the D2R receptor signaling gives a
positive or negative value (also in green or red, respectively). In (A), resting
condition. In (B,C), processing of a positive or a negative reward prediction
error, respectively.
associated with severe hypolocomotion and catalepsy (Bello et al.,
2017). Likewise, the spontaneous locomotor activity of A2AR−/−
mice was also significantly reduced, as previously reported in the
A2AR C57BL/6 mouse (Yang et al., 2009). Since pharmacological
blockade leads to significant locomotor activation (see below
and Karcz-Kubicha et al., 2003; Orrú et al., 2011a), the
reduced activity of A2AR−/− mice indicates the development
of neuroadaptations that counteract the loss of an A2AR-
mediated tonic inhibitory effect of endogenous adenosine on
psychomotor activity. We also assessed sensorimotor processing
of A2AR−/− and D2R−/− CD-1 mice by monitoring pre-pulse
inhibitory responses (PPI) (Taura et al., 2017). As compared with
WT mice, D2R−/− mice did not show significant differences,
while A2AR−/− mice showed a significantly reduced PPI as
previously reported (Wang et al., 2003; Moscoso-Castro et al.,
2016), demonstrating a significant dependence on A2AR, but
not D2R, signaling for a normal PPI. We also evaluated drug-
induced catalepsy in A2AR−/− and D2R−/− mice. Our results
showed that haloperidol-induced catalepsy was abolished and
partially but significantly reduced in D2R−/− and A2AR−/−
mice, respectively, as compared with WT mice (Taura et al.,
2017), which is in agreement with previous work (Usiello et al.,
2000; Chen et al., 2001; El Yacoubi et al., 2001). The results
support the dependence on A2AR signaling in the catalepsy
induced by pharmacological blockade of D2R, which would agree
with the existence of the tonic inhibition of A2AR signaling by
endogenous dopamine driven by the canonical interaction in
the A2AR-D2R heteromer. Neuroadaptations occurring in the
A2AR−/− mouse should explain the partial effect of genetic
blockade of A2AR on D2R antagonist-induced catalepsy, which
contrasts with the very effective blockade with A2AR antagonists
(see below and Kanda et al., 1994; Shiozaki et al., 1999; Morelli
and Wardas, 2001). We also assessed catalepsy induced by the
A2AR agonist CGS 21680 (Ferré et al., 1991a; Kanda et al., 1994;
Hauber and Münkle, 1997) in A2AR−/− and D2R−/− mice. As
expected, CGS 21680 failed to induce catalepsy in A2AR−/−
mice, but its effect was partially but significantly reduced in
D2R−/− mice (Taura et al., 2017). Again, these results might
reflect a functional antagonism related to neuroadaptations
associated with genetic D2R blockade, which would tend to
counteract the loss of the D2R-mediated tonic stimulatory effect
of endogenous dopamine on psychomotor activity.
We then reevaluated the effect of SCH 442416 on locomotion,
PPI and drug-induced catalepsy in WT, but also in A2AR−/−
and D2R−/− mice. In WT CD-1 mice, SCH 442416 produced
a significant and effective locomotor activation at 1 mg/kg (i.p.)
(Taura et al., 2017), a dose three times lower than the minimal
effective dose in Sprague-Dawley rats (Orrú et al., 2011a). As
expected, SCH 44241 was unable to alter the locomotor activity
in A2AR−/− mice and it only moderately, but significantly,
increased the activity in D2R−/− mice (Taura et al., 2017).
The decrease in the effect of the A2AR antagonist in D2R−/−
mice would agree with a dependence on D2R signaling in
the locomotor activation induced by pharmacological blockade
of A2AR, due to the tonic inhibition of D2R signaling by
endogenous adenosine driven by the allosteric interaction in the
A2AR-D2R heteromer. In agreement with the dependence on
A2AR for PPI, SCH 442416 (at the minimal dose of 3 mg/kg,
i.p.) induced a blockade of PPI in WT mice (Taura et al.,
2017). This is also in agreement with a previous study in
rats with intracranial infusion of another A2AR antagonist
(MSX-3) in the NAc (Nagel et al., 2003). SCH 442416 was
obviously ineffective on the already disrupted PPI in A2AR−/−
mice, but its disruptive effect was reduced in D2R−/− mice
(Taura et al., 2017). This could be related to the competing
effect of endogenous adenosine by the released tonic inhibition
of A2AR signaling by endogenous dopamine driven by the
canonical interaction in the A2AR-D2R heteromer. Finally, SCH
442416 significantly reduced haloperidol-induced catalepsy, as
previously reported for other A2AR antagonists (Kanda et al.,
1994; Shiozaki et al., 1999; Morelli and Wardas, 2001), but
with a higher minimal dose than the one needed to produce
locomotor activation (3 vs. 1 mg/kg, i.p., respectively; Taura
et al., 2017). To confirm the preferential pre- vs. postsynaptic
profile of SCH 442416 in mice, we also performed dose-
response experiments in C57BL/6 mice on locomotor activity
and counteraction of corticostriatal glutamate release using a
recently introduced optogenetic-microdialysis technique (Quiroz
et al., 2016; Bonaventura et al., 2017). Different to previous
experiments in rats, SCH 442416 showed the same potency
and efficiency as the selective A2AR antagonist KW 6002 at
Frontiers in Pharmacology | www.frontiersin.org 11 April 2018 | Volume 9 | Article 243
fphar-09-00243 April 6, 2018 Time: 17:35 # 12
Ferré et al. A2AR-D2R-AC5 Complexes Control Striatopallidal Neurons
eliciting locomotor activation. Both drugs produced significant
activation at 1 mg/kg (i.p.) but were inefficient at 0.1 mg/kg
(Figure 6A). At this moment, we do not have an explanation
for the lower potency and efficacy of SCH 442416 in rats as
compared to mice. On the other hand, SCH 442416 was able
to block optogenetically induced striatal glutamate release at
0.1 mg/kg, while KW 6002 was ineffective at 1 mg/kg (Figure 6B).
This confirmed the experimental findings in rats, demonstrating
a predominant striatal presynaptic and postsynaptic A2AR
blocking properties of SCH 442416 and KW 6002, respectively
(Orrú et al., 2011a).
Altogether, the results with genetic and pharmacological
blockade of A2AR and D2R agree with a main role of A2AR-D2R
heteromers in the striatopallidal neuron in conveying locomotor
activation and PPI disruption induced by A2AR antagonists and
D2R agonists and catalepsy mediated by A2AR agonists and D2R
antagonists. More specifically, they also agree with A2AR-D2R
heteromers in striatopallidal neurons mediating all postsynaptic
pharmacological effects of SCH 442416, locomotor activation,
blockade of PPI and counteraction of D2R antagonist-induced
catalepsy. As shown in the scheme of Figure 3A, the A2AR-
D2R heteromer explains the qualitatively different behavioral
outputs depending on direct A2AR-Golf-AC-PKA-mediated
increase in excitability or indirect D2R-Gi-PLC-PP2B-mediated
disinhibition of the excitability of the striatopallidal neuron,
leading to catalepsy and PPI (more related to the direct activation
of the PKA-DARPP-32-CREB signaling; Bateup et al., 2010;
Berger et al., 2011) or just psychomotor depression, respectively.
In fact, it is well known that catalepsy, with its rigidity
component, is not qualitatively equivalent to a high degree
of locomotor depression. Finally, and as mentioned before,
depending on the intracellular concentrations of Ca2+, A2AR
and D2R activation and co-activation lead to differential MAPK
and Elk-1 activation, with implications for gene expression and
synaptic plasticity (Figure 3A).
A2AR-D2R HETEROMER-MEDIATED
CONTROL OF THE VENTRAL VS.
DORSAL STRIATOPALLIDAL FUNCTION
AND IMPLICATIONS FOR
NEUROPSYCHIATRIC DISORDERS.
‘APATHY’ VS. ‘AKINESIA’
Dysfunction of the central dopamine system is involved in a
variety of disorders, including Parkinson’s disease, schizophrenia,
and substance use disorders (SUD). The functional separation
of striatal compartments in ventral, rostral-dorsal and caudal-
dorsal striata allows a more syndromic sub-classification of
those disorders with potentially significant new therapeutic
approaches. Parkinson’s disease and non-human primate models
of Parkinson’s disease provide the clearest illustration. The
cardinal motor symptoms of Parkinson’s disease, bradykinesia,
rigidity and tremor (Jankovic, 2008), have been classically
attributed to dysfunction of the skeletomotor system, the brain
FIGURE 6 | Preferential presynaptic profile of SCH 442416 in C57BL/6 mice. (A) SCH 442416 shows similar potency and efficacy to KW 6002 at producing
locomotor activation. Locomotor activity was measured in an open field arena as described elsewhere (Bonaventura et al., 2015); animals were injected
intraperitoneally (i.p.) with vehicle (saline with 10% DMSO and 10% Tween-80) and the indicated concentrations of SCH 442416 or KW 6002 and the locomotor
activity was measured for 2 h in activity chambers with 42.0 cm × 42.0 cm open fields (Coulbourn Instruments); values are mean ± SEM of the traveled distance
(arbitrary units, A.U.); two-way ANOVA with Newman–Keuls post hoc test did not demonstrate significant differences between the two A2AR antagonists and, for
both drugs, it only showed significant differences with the dose of 1 mg/kg as compared to the corresponding vehicle-treated groups (∗∗p < 0.01 compared to
vehicle; n = 8–11). (B) Optogenetic-microdialysis experiments were performed as described elsewhere (Bonaventura et al., 2017); briefly, C57BL/6 mice received a
unilateral injection of an AAV encoding ChR2 (ChR2/H134R) fused to EYFP under control of the CaMKIIa neuronal promoter [AAV-CaMKIIa-hChR2(H134R)-EYFP] in
the motor cortex. One month later, an optogenetic-microdialysis probe (Quiroz et al., 2016; Bonaventura et al., 2017) was implanted in the dorsal striatum, and
glutamate in the dialysate was measured at 10-min intervals before, during, and after optogenetic stimulation of the corticostriatal terminals. Vehicle (black plot, see
above) or the indicated doses of SCH 442416 (red plot) or KW 6002 (blue plot) were administered (i.p.) 10 min before the start of the stimulation. Values (in % over
basal) represent mean ± SEM, normalized to the mean of the concentration of GLU present in the three samples preceding stimulation; one-way ANOVA with
Newman–Keuls post hoc test showed a significant decrease of the transformed values (area under the curve, data from min 0 to min 60) from both groups treated
with SCH 442416 (1 and 0.1 mg/kg), but not from the group treated with KW 6002, compared to the vehicle group (∗∗p < 0.01 compared to vehicle;
ns, non-significant; n = 7–8).
Frontiers in Pharmacology | www.frontiersin.org 12 April 2018 | Volume 9 | Article 243
fphar-09-00243 April 6, 2018 Time: 17:35 # 13
Ferré et al. A2AR-D2R-AC5 Complexes Control Striatopallidal Neurons
circuits involved in the execution and coordination of body
movements. Contemporary theories embracing parallel cortical-
striatal-thalamic-cortical circuits in the pathogenesis of this
disorder emphasize the particular involvement of the “motor
circuit,” which includes motor cortical areas (DeLong and
Wichmann, 2015). In fact, in Parkinson’s disease, dopamine
cell degeneration tends to occur initially and predominantly
in the lateral part of the SNpc, which projects mainly to the
caudal-dorsal striatum. Thus, there is a predominant deficit
of the more “automatic” vs. “volitional” action skills and
most sequential psychomotor responses need to be performed
with full attention (Kim and Hikosaka, 2015). Nevertheless,
with more advanced stages of Parkinson’s disease the function
of the more rostral striatum becomes also compromised,
with deficits in “volitional” actions skills (Kim and Hikosaka,
2015). With further (or preferential) ventral degeneration of
the dopamine mesencephalic nuclei (VTA) we move to the
pathology of the ventral striatum, to apathy (Tremblay et al.,
2015), as it has also been demonstrated experimentally in
the non-human primate (Brown et al., 2012; Tian et al.,
2015).
Initial studies on the psychomotor-activating effects of
caffeine or selective A2AR antagonists dealt with general
locomotor activity and were translationally applied to the
treatment of akinesia in Parkinson’s disease (see above and
Müller and Ferré, 2007; Morelli et al., 2009; Armentero
et al., 2011). Those initial studies implicitly considered A2AR-
D2R heteromers in the dorsal striatum, but a large number
of studies indicated that not only dorsal but also ventral
striatopallidal neurons express A2R and A2AR-D2R heteromers
(Ferré et al., 1994; Ferré, 1997; Hauber and Münkle, 1997;
Pinna et al., 1997; Svenningsson et al., 1997; Ishiwari et al.,
2007). More recent studies have also analyzed the effect of
caffeine and A2AR antagonists on more specific reward-oriented
behaviors, showing that they can increase the responsiveness
to food-related stimuli, sucrose solutions, stimuli that elicit
maternal behavior and self-administration (Pereira et al., 2011;
Randall et al., 2011; Sheppard et al., 2012; Nunes et al.,
2013; Lazenka et al., 2015). The work by Salamone’s group
has specifically addressed the role of adenosine and A2AR in
effort-related choice behavior. Direct administration of A2AR
agonists in the NAc altered effort-related choice behavior in
a manner closely resembling the effects of interference with
ventral striatal dopamine neurotransmission, decreasing the
degree of responsiveness (“effort”) to reward-associated stimuli.
Furthermore, A2AR antagonists reversed the effort discounting
effects of D2R antagonists (Salamone et al., 2012; Nunes et al.,
2013).
Clinically, apathy has been defined as “a syndrome consisting
of loss of motivation not attributable to disturbances in
emotion, intellect or consciousness” (Marin, 1991). However,
it is becoming obvious that apathy is a multifaceted concept
that includes dissociable constructs that should correspond to
dissociable neurobiological correlates (Sinha et al., 2013). We
hypothesize that some if not all those dissociable correlates
correspond to corticostriatal circuits involving the different
functional striatal compartments and their “Go” and “NoGo”
pathways. In fact, attuned with the role of dopamine in reward-
associated behavior in all striatal compartments, recent studies
even allow conceptualizing Parkinson’s disease bradykinesia in
a motivational framework (Mazzoni et al., 2007; Chong et al.,
2015). Nevertheless, as defined clinically, apathy is a common
non-motor symptom of Parkinson’s disease (den Brok et al.,
2015) that correlates negatively with dopamine innervation
in the ventral striatum (Remy et al., 2005; Chaudhuri et al.,
2006; Brown et al., 2012). In fact, a deficit in the dopamine
modulation of the ventral striatum should translate, first, in
a deficit in responsiveness, with a global inability to respond
to reward- and punishment-associated stimuli (attuned with
the “whether to respond” vs. “how to respond” functions of
ventral vs. dorsal striatum). Second, it should lead to dysfunction
of reward valuation, in alterations (increase) in DD, ED and
LPD (attuned with the ventral striatum as forming part of
corticostriatal circuits involved in reward valuation tasks).
Indeed, non-medicated patients with Parkinson’s disease have
shown increases in DD and ED (Al-Khaled et al., 2015; Chong
et al., 2015).
Interestingly, apathy is also a major negative symptom of
schizophrenia, classically considered as a disorder associated
with central hyperdopaminergic tone. Several studies have found
evidence for selective dysfunction of the ventral striatum in
schizophrenia, specifically hypoactivation with reward-associated
stimuli (Simon et al., 2010, 2015; Strauss et al., 2015; Kirschner
et al., 2016). Ventral striatal activation during reward anticipation
was in fact found to be selectively and inversely correlated with
apathy but not with other negative symptoms (Simon et al.,
2010; Kirschner et al., 2016). Two additional findings give a
clue for the mechanisms of apathy in schizophrenia, which
seem to be dopamine-independent or at least not related to
a decrease in the dopamine tone. First, there is a reduced
functional connectivity between the orbito-frontal cortex (OFC)
and the ventral striatum (Simon et al., 2015); second, there
is consistent evidence that schizophrenic patients suffer from
selective deficits in learning from positive outcomes, with intact
learning from negative outcomes (Strauss et al., 2015). Therefore,
the apathetic schizophrenic patient seems to have a selective
decreased activation of the “Go” pathway, a reduction in the
ratio of activation of “Go” vs. “NoGo” pathways secondary
to impaired cortical-ventral striatal connectivity (Strauss et al.,
2015). A similar situation would also be present in the patient
with SUD, a decreased “Go”/“NoGo” pathway activation, also
with reduced ventral striatal activation to reward stimuli
(which can basically only be activated by the addictive drugs)
(Volkow et al., 2011). Apathy is a well-known symptom in
SUD, although it has been scarcely addressed experimentally
(Verdejo-García et al., 2006; Verdejo-García and Pérez-García,
2008; Gjini et al., 2014). The SUD patient is motivated to
procure the drug but tends to be withdrawn and apathetic
when exposed to non-drug-related activities (Verdejo-García
et al., 2006). In this case, however, the pathogenesis seems to
follow from an initial reduction in D2R density (maybe with
a concomitant relative increase of A2AR which would not be
opposed by D2R forming heteromers), leading to an increased
activity of the ventral striatopallidal neuronal function, of the
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“NoGo” pathway. The tonic decrease in feedback activation of the
ventromedial prefrontal cortex, orbitofrontal cortex and anterior
cingulate cortex leads to additional dysfunction of the decision-
making cortical-ventral striatal circuits (Volkow et al., 2011;
Belcher et al., 2014). These changes lead to a similar situation than
the non-motor symptoms in patients with Parkinson’s disease,
to apathy and choice impulsivity, as demonstrated by several
studies indicating increase DD in patients with SUD (Belcher
et al., 2014; Hamilton et al., 2015). In summary, for all types
of apathy, the relative increase in the ventral striopallidal vs.
striatonigral neuronal function should benefit from the treatment
with A2AR antagonists, targeting A2AR-D2R heterotetramer-
AC5 complexes.
CONCLUSION
A significant amount of experimental and clinical evidence
demonstrates that A2AR and D2R localized in the ventral and
dorsal striatopallidal neurons cannot be considered anymore
as single functional units, but as forming part of complexes
of the A2AR-D2R heterotetramer-AC5 complexes, which
exert a fine-tuned integration of adenosine and dopamine
neurotransmission. The current accumulated knowledge of
the biochemical properties of the A2AR-D2R heteromer
offer new therapeutic possibilities for Parkinson’s disease,
schizophrenia, SUD and other neuropsychiatric disorders with
dysfunction of dorsal or ventral striatopallidal neurons. More
generally, this knowledge implies we should modify classical
views of GPCR physiology and pharmacology and include
GPCR heteromers as main targets for drug development.
The understanding of the biochemical properties of GPCR
heteromers specifically localized in neuronal elements that
form part of neuronal circuits involved in the pathophysiology
of specific neuropsychiatric disorders should provide new
selective pharmacological approaches with less unwanted side
effects.
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